Search

Search Constraints

You searched for: Author/Creator Tan, E.H.

Search Results

3. 461 Individualized molecular profiling for allocation to clinical trials (impact) - experience from an Asian tertiary cancer centre. (September 2015)

4. Afatinib vs gefitinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7). (February 2017)

5. Evolutionary trajectory of Asian EGFR mutation positive lung adenocarcinomas leads to "high intratumor heterogeneity". (July 2016)

6. First-line afatinib for advanced EGFR mutation-positive (EGFRm+) NSCLC: analysis of long-term responders in the Phase III LUX-Lung 3, 6 and 7 trials. (February 2017)

8. The TBL1 inhibitor, Tegavivint, suppresses tumour growth and enhances T-cell infiltration in preclinical murine β-Catenin mutant hepatocellular carcinoma. (October 2022)